Clinical trial
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk…
NCT00353522 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00353522 |
|---|---|
| Title | A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent. |
| Official title | A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Heart Disease |
| Intervention type | Drug |
| Interventions | Placebo, dalcetrapib |
| Enrollment | 135 |
| Start date | Jul 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jul 18, 2006 |
| Last update posted | Jan 27, 2020 |
| Countries | Germany, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: